INTRODUCTION
Hepatocellular carcinoma (HCC) is probably the commonest malignant tumour in males in the world and is responsible for approximately 1,000,000 deaths annually1'2. In China, most of Southeast Asia and Sub-Saharan Africa it occurs at a rate of 20 to 150 per 100,000 a year, whilst in the USA and Europe the rate ranges from 1 to 5 per 100,000 a year3 '4 . In all countries it shows a marked male preponderance. Evidence for the role of the HBV comes mainly from epidemiological studies. The worldwide prevalence of HBV infection is at least ten-times higher in Southeast Asia and Africa than in North America and Western Europe and this parallels the incidence of HCC. In addition there seems to be an increase in the prevalence of HBV-markers in patients with HCC when compared to the local population. A prospective study in Taiwan determined that the relative risk of developing HCC was more than 200-fold greater in individuals who were HBsAg (Hepatitis B surface antigen) carriers 6 and the risk is said to be greater when the carrier state is acquired in early life5'6'7. The precise mechanism by which persistent HBV infection and the development of HCC are related remains largely unknown.
Chronic carriage and cirrhosis seem to need to exist for 
SCREENING
As with many cancers it has been suggested that early diagnosis offers the best chance of cure. Evidence for this proposal has now emerged from the reports of the 26 38 40 Liver Cancer Study Group of Japan They suggest that patients with chronic liver disease, particularly cirrhosis, should be followed at regular intervals using ultrasound(US) and measurement of alpha-fetoprotein. 
